MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration AMD at Association for Research in Vision and Ophthalmology ARVO 2026
MingMed Biotechnology ha presentato i risultati positivi di uno studio di fase II sul farmaco orale QA102, destinato al trattamento della degenerazione maculare legata all’età di grado intermedio. L’annuncio è stato fatto durante l’assemblea dell’Association for Research in Vision and Ophthalmology (ARVO) 2026, tenutasi nel mese di maggio a Guangzhou. I dati riguardano un trattamento sperimentale in corso di sviluppo da parte dell’azienda.
COMUNICATO STAMPA – CONTENUTO PROMOZIONALE GUANGZHOU, China, May 6, 2026 PRNewswire — MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado. Intermediate dry AMD is a chronic, progressive retinal disease marked by large drusen and pigmentary changes, representing a significant risk for conversion to advanced AMD.🔗 Leggi su Corrieretoscano.it
Notizie correlate
Leggi anche: Oral-b Spazzolino Elettrico Oral-b Pro3: vale la pena?
Aruba entra nell’International Data Spaces AssociationFocus su modello “as-a-service” e semplificazione dell’accesso per le Pmi, in linea con le evidenze emerse al Data Space Symposium Bergamo.
Contenuti utili per approfondire
Argomenti più discussi: MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026; Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 De?ciency Disorder.
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in ...MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinica ... adnkronos.com
MingMed Biotechnology Co., Ltd: MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at ...MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas ... finanznachrichten.de
➜